ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. trimmed its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 98.4% during the 3rd quarter, according to its most recent disclosure with...
MarketBeat·11h ago
More News
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Here's Why
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Should You Buy...
MarketBeat·4d ago
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·4d ago
Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD
Hohimer Wealth Management LLC decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 26.6% during the 2nd quarter, according to its most recent disclosure with the SEC...
MarketBeat·12d ago
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD
TFG Asset Management GP Ltd raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 50.8% in the 2nd quarter, according to its most recent Form 13F filing with the...
MarketBeat·13d ago
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Eventide Asset Management LLC decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 14.6% in the second quarter, according to its most recent Form 13F filing...
MarketBeat·13d ago
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Birchview Capital LP lessened its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 28.7% in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·13d ago
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free...
Business Wire·14d ago
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $928,000 Position in ACADIA Pharmaceuticals Inc. $ACAD
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the second quarter, according...
MarketBeat·14d ago
Stifel Nicolaus Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price
Stifel Nicolaus boosted their target price on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a "hold" rating in a research note on Thursday...